Another in vitro study demonstrated that Citarinostat reduced the production of Th2 cytokines (e.g., IL-4, IL-5, IL-6, IL-10, IL-13) in melanoma models, enhanced cytotoxic activity in mixed lymphocyte reactions, and downregulated the Tregs/FOXP3 axis, thereby potentiating T-cell-mediated anti-tumor responses in melanoma [131]. The gene discussed is IL6; the disease is melanoma.